Ovid Therapeutics logo

Ovid Therapeutics Share Price (NASDAQ: OVID)

$1.09

0.06

(5.83%)

Live

Last updated on

Check the interactive Ovid Therapeutics Stock chart to analyse performance

Ovid Therapeutics stock performance

as on August 26, 2025 at 12:39 AM IST

  • Today's Low:$1.08
    Today's High:$1.09

    Day's Volatility :0.92%

  • 52 Weeks Low:$0.24
    52 Weeks High:$1.47

    52 Weeks Volatility :83.5%

Ovid Therapeutics Stock Returns

PeriodOvid Therapeutics IncIndex (Russel 2000)
3 Months
253.47%
0.0%
6 Months
80.58%
0.0%
1 Year
-20.77%
0.0%
3 Years
-51.87%
-10.0%

Ovid Therapeutics Inc Key Stats

Check Ovid Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.03
Open
$0.949
Today's High
$1.17
Today's Low
$1.055
Market Capitalization
$73.2M
Today's Volume
$1.2M
52 Week High
$1.47
52 Week Low
$0.2425
Revenue TTM
$6.7M
EBITDA
$-41.2M
Earnings Per Share (EPS)
$-0.54
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-52.77%

Stock Returns calculator for Ovid Therapeutics Stock including INR - Dollar returns

The Ovid Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ovid Therapeutics investment value today

Current value as on today

₹88,181

Returns

₹11,819

(-11.82%)

Returns from Ovid Therapeutics Stock

₹16,154 (-16.15%)

Dollar Returns*

₹4,335 (+4.33%)

Indian investors sentiment towards Ovid Therapeutics Stock

29%

Period: Jul 25, 2025 to Aug 24, 2025. Change in 30 Days versus previous period

Search interest for Ovid Therapeutics Stock from India on INDmoney has increased by 29% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Ovid Therapeutics Inc

  • Name

    Holdings %

  • Takeda Pharmaceutical Co Ltd

    10.59%

  • BlackRock Inc

    5.43%

  • Bvf Inc

    5.42%

  • Vanguard Group Inc

    3.71%

  • Sio Capital Management, LLC

    3.14%

  • Acadian Asset Management LLC

    2.94%

Analyst Recommendation on Ovid Therapeutics Stock

Rating
Trend

Buy

    87%Buy

    12%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Ovid Therapeutics(by analysts ranked 0 to 5 stars)

Ovid Therapeutics Share Price Target

What analysts predicted

Upside of 211.93%

Target:

$3.40

Current:

$1.09

Ovid Therapeutics share price target is $3.40, a slight Upside of 211.93% compared to current price of $1.09 as per analysts' prediction.

Ovid Therapeutics Stock Insights

  • Price Movement

    In the last 3 months, OVID stock has moved up by 261.0%
  • Increasing Revenue

    Revenue is up for the last 3 quarters, 76.0K → 6.27M (in $), with an average increase of 69.7% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -10.23M → -4.68M (in $), with an average increase of 118.5% per quarter
  • OVID vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.7% return, outperforming this stock by 81.6%
  • OVID vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.4% return, outperforming this stock by 166.0%
  • Price to Sales

    ForOVID every $1 of sales, investors are willing to pay $11.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Ovid Therapeutics Technicals Summary

Sell

Neutral

Buy

Ovid Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Ovid Therapeutics Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Ovid Therapeutics Inc logo
95.26%
80.58%
-20.77%
-51.87%
-83.0%
Regeneron Pharmaceuticals, Inc. logo
5.52%
-17.35%
-50.85%
-1.12%
-3.68%
Beone Medicines Ltd logo
6.51%
21.35%
57.45%
73.21%
25.84%
Vertex Pharmaceuticals Incorporated logo
-14.26%
-17.97%
-18.13%
40.27%
45.64%
Alnylam Pharmaceuticals, Inc. logo
39.9%
82.53%
68.83%
115.41%
241.51%

About Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Organization
Ovid Therapeutics
Employees
23
CEO
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Industry
Health Technology

Key Management of Ovid Therapeutics Inc

NameTitle
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
CEO & Chairman
Ms. Margaret Alexander
President & COO
Mr. Jeffrey A. Rona
Chief Business and Financial Officer
Dr. Zhong Zhong Ph.D.
Chief Scientific Officer
Dr. Amanda Banks M.D.
Chief Development Officer
Dr. Dirk Haasner
Senior Vice President of Global Manufacturing & CMC QA
Dr. Julia Tsai Ph.D.
Senior Vice President of Clinical Development
Dr. Toshiya Nishi D.V.M.
Head of Epilepsy Research
Dr. Manal Morsy M.B.A., M.D., PH.D.
Chief Regulatory Officer
Ms. Victoria Fort
Senior Vice President of Corporate Affairs & Corporate Strategy

Important FAQs about investing in OVID Stock from India :

What is Ovid Therapeutics share price today?

Ovid Therapeutics share price today is $1.09 as on . Ovid Therapeutics share today touched a day high of $1.09 and a low of $1.08.

What is the 52 week high and 52 week low for Ovid Therapeutics share?

Ovid Therapeutics share touched a 52 week high of $1.47 and a 52 week low of $0.24. Ovid Therapeutics stock price today i.e. is trending at $1.09, lower by 25.85% versus the 52 week high.

How to invest in Ovid Therapeutics Stock (OVID) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Ovid Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ovid Therapeutics Shares that will get you 1.3761 shares as per Ovid Therapeutics share price of $1.09 per share as on August 26, 2025 at 12:39 AM IST.

What is the minimum amount required to buy Ovid Therapeutics Stock (OVID) from India?

Indian investors can start investing in Ovid Therapeutics (OVID) shares with as little as ₹87.537 or $1 (as of August 25, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.37 in Ovid Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 25, 2025). Based on Ovid Therapeutics share’s latest price of $1.09 as on August 26, 2025 at 12:39 AM IST, you will get 9.1743 shares of Ovid Therapeutics. Learn more about fractional shares .

What are the returns that Ovid Therapeutics has given to Indian investors in the last 5 years?

Ovid Therapeutics stock has given -83.0% share price returns and 18.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?